OrthoPediatrics Corp. (NASDAQ:KIDS) Receives $24.67 Consensus Price Target from Analysts

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) have been given a consensus recommendation of “Moderate Buy” by the eleven ratings firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $24.6667.

KIDS has been the subject of a number of analyst reports. Canaccord Genuity Group assumed coverage on OrthoPediatrics in a report on Wednesday, December 10th. They issued a “buy” rating and a $24.00 price target for the company. Needham & Company LLC lifted their price objective on shares of OrthoPediatrics from $26.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Wall Street Zen raised shares of OrthoPediatrics from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. Weiss Ratings restated a “sell (e+)” rating on shares of OrthoPediatrics in a research note on Thursday, January 22nd. Finally, Truist Financial raised their price target on shares of OrthoPediatrics from $19.00 to $20.00 and gave the company a “hold” rating in a report on Monday, March 2nd.

OrthoPediatrics Price Performance

Shares of NASDAQ KIDS opened at $16.06 on Friday. The stock has a fifty day moving average price of $17.06 and a 200 day moving average price of $17.57. The company has a current ratio of 5.55, a quick ratio of 2.65 and a debt-to-equity ratio of 0.28. OrthoPediatrics has a 12-month low of $14.91 and a 12-month high of $25.73. The company has a market cap of $405.98 million, a P/E ratio of -9.50 and a beta of 1.16.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.11. OrthoPediatrics had a negative return on equity of 6.70% and a negative net margin of 16.77%.The company had revenue of $61.61 million for the quarter, compared to analysts’ expectations of $61.27 million. Research analysts anticipate that OrthoPediatrics will post -0.93 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Fred Hite sold 12,993 shares of the firm’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $17.25, for a total transaction of $224,129.25. Following the completion of the sale, the chief financial officer directly owned 277,477 shares in the company, valued at $4,786,478.25. This trade represents a 4.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Gregory A. Odle sold 8,433 shares of OrthoPediatrics stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $17.25, for a total value of $145,469.25. Following the sale, the insider directly owned 187,735 shares in the company, valued at approximately $3,238,428.75. The trade was a 4.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 58,171 shares of company stock worth $1,003,450 over the last quarter. Company insiders own 32.70% of the company’s stock.

Institutional Investors Weigh In On OrthoPediatrics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Prosight Management LP increased its stake in shares of OrthoPediatrics by 319.2% in the third quarter. Prosight Management LP now owns 308,707 shares of the company’s stock worth $5,720,000 after buying an additional 235,060 shares during the last quarter. Grandeur Peak Global Advisors LLC acquired a new stake in OrthoPediatrics in the second quarter valued at $452,000. Inceptionr LLC bought a new position in OrthoPediatrics during the 3rd quarter valued at $265,000. Triodos Investment Management BV boosted its stake in OrthoPediatrics by 17.8% during the 3rd quarter. Triodos Investment Management BV now owns 132,500 shares of the company’s stock valued at $2,454,000 after acquiring an additional 20,000 shares during the last quarter. Finally, Birchview Capital LP grew its holdings in OrthoPediatrics by 30.0% during the 2nd quarter. Birchview Capital LP now owns 26,000 shares of the company’s stock worth $558,000 after acquiring an additional 6,000 shares in the last quarter. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.